Entry of elemental arsenic into the central nervous system in patients with acute promyelocytic leukemia during arsenic trioxide treatment

Leukemia Research

Volumn 32, Issue 2, 2008, Pages 357-358

  Au, Wing Yan ^a   Tam, Sidney ^a   Kwong, Yok Lam ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE;

ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; BLOOD BRAIN BARRIER; CELL DEATH; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG ELIMINATION; DRUG PENETRATION; GAS CHROMATOGRAPHY; HUMAN; MASS SPECTROMETRY; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA;

EID: 38949197430     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.06.005     Document Type: Note

References (6)

1. Knipp S, Gattermann N, Schapira M, Kaferstein H, Germing U. Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement. Leuk Res 2007 [Epub ahead of print].
2. Au W.Y., Tam S., Fong B.M., and Kwong Y.L. Elemental arsenic entered the cerebrospinal fluid during oral arsenic trioxide treatment of meningeal relapse of acute promyelocytic leukemia. Blood 107 (2006) 3012-3013
3. Leung J., Pang A., Yuen W.H., Kwong Y.L., and Tse E.W. Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells. Blood 109 (2007) 740-746
4. Kumana C.R., Au W.Y., Lee N.S., Kou M., Mak R.W., Lam C.W., et al. Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies. Eur J Clin Pharmacol 58 (2002) 521-526
5. 3 exerts dose-dependent dual effects on APL cells. Blood 89 (1997) 3345-3353
6. Au W.Y., Ma S.K., Ooi C., Liang R., and Kwong Y.L. Unusual manifestations of acute leukaemia. Case 1. CNS extramedullary relapse of acute promyelocytic leukemia after arsenic trioxide-induced remission. J Clin Oncol 18 (2000) 3435-3437